JMFC
REGN icon

J.M. Forbes & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

J.M. Forbes & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-519
Closed -$370K – 142
2024
Q4 		$370K Buy
519
+312
+151% +$262K 0.04% 116
2024
Q3 		$218K Buy
207
+8
+4% +$8.9K 0.02% 136
2024
Q2 		$209K Buy
+199
New +$193K 0.02% 130

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J.M. Forbes & Co's REGN Position: Q1 2025 in Review

J.M. Forbes & Co sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 519 shares — an estimated $370K sold.

J.M. Forbes & Co first reported a position in REGN in Q2 2024 and held it in 3 quarters. The position peaked at $370K in Q4 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • J.M. Forbes & Co reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • J.M. Forbes & Co sold 519 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $370K.
  • J.M. Forbes & Co first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • J.M. Forbes & Co's Regeneron Pharmaceuticals position peaked at $370K in Q4 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on J.M. Forbes & Co's 13F filing for Q1 2025, filed 6 May 2025.